Literature DB >> 26444485

Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.

Lian Lian1,2, You-You Xia3,4, Chong Zhou5, Xiao-Ming Shen2, Xiang-Li Li6, Shu-Guang Han6, Yan Zheng2, Zhong-Qi Mao7, Fei-Ran Gong8, Meng-Yao Wu1, Kai Chen1, Min Tao1,9,10,11, Wei Li1,11.   

Abstract

BACKGROUND: Gastric cancer is the fourth most frequent cancer and the second cause of cancer-related deaths worldwide. China has a high incidence of gastric cancer. Inflammation is a critical component of tumor progression. It has been widely accepted that gastric cancer is an inflammation-driven cancer. In this study, we investigated the application value of systemic inflammatory response (SIR) markers, platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR), in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
MATERIALS AND METHODS: One hundred and sixty-two patients with resectable gastric cancer were included and separated into groups according to median pre-operative PLR or NLR values (PLR low: < 208 or PLR high: ≥ 208, and NLR low: < 4.02 or NLR high: ≥ 4.02, respectively). To evaluate the changes in PLR or NLR values after operation, we introduced the concept of postpre-operative PLR or NLR ratios (< 1 indicated PLR or NLR values were decreased after operation, while ≥ 1 suggested not decreased PLR or NLR values).
RESULTS: Pre-operative PLR and NLR levels were significantly higher in gastric cancer patients compared with the healthy subjects. Low pre-operative PLR and NLR levels correlated with better clinicopathological features, including decreased depth of invasion, less lymph node metastasis and early tumor stage. Kaplan-Meier plots illustrated that higher pre-operative NLR and PLR had decreased overall survival (OS) and disease-free survival (DFS). Surgical tumor resection resulted in a significant
CONCLUSIONS: PLR and NLR measurements can provide important diagnostic and prognostic results in patients with resectable gastric cancer.

Entities:  

Keywords:  Gastric cancer; neutrophil to lymphocyte ratio (NLR); platelet to lymphocyte ratio (PLR)

Mesh:

Substances:

Year:  2015        PMID: 26444485     DOI: 10.3233/CBM-150534

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  42 in total

Review 1.  Neutrophils in the Tumor Microenvironment.

Authors:  Davalyn R Powell; Anna Huttenlocher
Journal:  Trends Immunol       Date:  2015-12-14       Impact factor: 16.687

2.  Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection.

Authors:  Daisuke Kuroda; Hiroshi Sawayama; Junji Kurashige; Masaaki Iwatsuki; Tsugio Eto; Ryuma Tokunaga; Yuki Kitano; Kensuke Yamamura; Mayuko Ouchi; Kenichi Nakamura; Yoshifumi Baba; Yasuo Sakamoto; Yoichi Yamashita; Naoya Yoshida; Akira Chikamoto; Hideo Baba
Journal:  Gastric Cancer       Date:  2017-06-27       Impact factor: 7.370

3.  Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma.

Authors:  Zu-Yang Yuan; Shu-Geng Gao; Ju-Wei Mu; Qi Xue; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yu-Shun Gao; Jin-Feng Huang; Jie He
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients.

Authors:  Weipeng Gong; Lei Zhao; Zhaogang Dong; Yu Dou; Yanguo Liu; Chao Ma; Xun Qu
Journal:  J Clin Lab Anal       Date:  2017-12-18       Impact factor: 2.352

5.  Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratio with visual acuity and macular thickness in age-related macular degeneration.

Authors:  Elvan Alper Sengul; Ozgur Artunay; Alev Kockar; Ceyda Afacan; Rifat Rasier; Palmet Gun; Nazli Gul Yalcin; Erdal Yuzbasioglu
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

6.  Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy.

Authors:  Jian-Xian Lin; Jun-Peng Lin; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ruhong Tu; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Oncologist       Date:  2019-03-25

7.  Novel prognostic scoring system for diffuse large B-cell lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Zhijie Yue; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Zhigang Zhao; Yizhuo Zhang; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

8.  Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio Cannot Predict Lymph Node Metastasis and Prognosis in Patients with Early Gastric Cancer: a Single Institution Investigation in China.

Authors:  Guang-Sheng Zhu; Shao-Bo Tian; Hui Wang; Mao-Guang Ma; Ya Liu; Han-Song Du; Yue-Ping Long
Journal:  Curr Med Sci       Date:  2018-03-15

9.  Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.

Authors:  Hirokazu Kubo; Takashi Murakami; Ryusei Matsuyama; Yasuhiro Yabushita; Nobuhiro Tsuchiya; Yu Sawada; Yuki Homma; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

10.  Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Eliza W Beal; Lai Wei; Cecilia G Ethun; Sylvester M Black; Mary Dillhoff; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Timothy M Pawlik; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt
Journal:  HPB (Oxford)       Date:  2016-09-24       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.